Picamilon, a γ-aminobutyric acid (GABA) analogue and marketed nootropic, is inactive against 50 biological targets
Santillo MF, Sprando RL · 2023 · Basic & clinical pharmacology & toxicology 132(4). PMID 36668678
What does this source report?
Picamilon showed weak or no binding at 10 μM across the tested panel. This does not exclude other targets, metabolites or effects at other concentrations.
- Population and setting
- 50 biological targets; computational and in-vitro screening
- Evidence type
- In vitro
- Preparation
- See the original report; formulation details require verification.
- Source language
- English
- Title provenance
- Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.
What are the limitations?
- Full methods and risk of bias have not been appraised.
- These findings do not establish long-term, combination or hazardous-work safety.
- Related reports may share participants; source records are not independent-trial counts.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Source access and review scope
Indexed citation and abstract checked through Europe PMC; full paper not reviewed.
Recorded source-check date: 2026-09-30. This date does not imply a completed systematic review.
Open original source or index record ↗
DOI: 10.1111/bcpt.13836
Cite and trace this record
Original source: Santillo MF, Sprando RL. Picamilon, a γ-aminobutyric acid (GABA) analogue and marketed nootropic, is inactive against 50 biological targets Basic & clinical pharmacology & toxicology 132(4). PMID 36668678 2023.
Molekul research summary: https://molekul.io/research/pic-36668678. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry